Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kendra L. Sweet"'
Autor:
Andrew T. Kuykendall, Qianxing Mo, David A. Sallman, Najla Al Ali, Onyee Chan, Seongseok Yun, Kendra L. Sweet, Eric Padron, Jeffrey E. Lancet, Rami S. Komrokji
Publikováno v:
Cancer. 128:3495-3501
Thrombocytopenia in patients with myelofibrosis (MF) is prognostically detrimental and poses a therapeutic challenge. MF patients with thrombocytopenia are considered high-risk by most prognostic models and their distinct phenotype has given rise to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c522b530836e7800b0a9e47756af57bc
https://doi.org/10.1002/cncr.34414
https://doi.org/10.1002/cncr.34414
Autor:
Rami S. Komrokji, Luis E. Aguirre, Najla Al-Ali, Onyee Chan, Zhuoer Xie, Andrew T. Kuykendall, Kendra L Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman
Publikováno v:
Blood Advances.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e98246aa7c234368782ecdcb88fc9ac1
https://doi.org/10.1182/bloodadvances.2023009781
https://doi.org/10.1182/bloodadvances.2023009781
Autor:
Kendra L. Sweet, Jorge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler, Cristina Ruiz, Charles A. Schiffer, Lori A. Ehrlich, Gulsum E. Pamuk, Joseph Wynne, Gautam U. Mehta, R. Angelo de Claro, Marc R. Theoret, B. Douglas Smith, Kelly J. Norsworthy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
The FDA has an accelerated approval program for drugs that have been identified as promising treatments for serious conditions when the available data suggest that the benefits outweigh the foreseeable risks. All of the currently available treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc23751589223de30fca3b8ddbee69cc
https://pubmed.ncbi.nlm.nih.gov/36547666
https://pubmed.ncbi.nlm.nih.gov/36547666
Autor:
Sarit Assouline, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Cheema, Kendra L. Sweet, Adam S. Asch, Jijun (Jane) Liu, Anna B. Moseley, Tracy Maher, Laura L. Kingsbury, Min Fang, Jerald Radich, Richard F. Little, Harry P. Erba
Publikováno v:
Leukemialymphoma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc71e8c82b561a15cb597ea583e1236a
https://pubmed.ncbi.nlm.nih.gov/36517990
https://pubmed.ncbi.nlm.nih.gov/36517990
Autor:
Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, Eunice S. Wang, David A. Rizzieri, Sumithira Vasu, Todd L. Rosenblat, Christopher L. Brooks, Nassir Habboubi, Tariq I. Mughal, Hagop Kantarjian, Marina Konopleva, Andrew A. Lane
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(26)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75233288aecd64a17d9406b7f908ae6
https://pubmed.ncbi.nlm.nih.gov/35820082
https://pubmed.ncbi.nlm.nih.gov/35820082
Autor:
Somedeb Ball, Todd C. Knepper, Yehuda E. Deutsch, Wassim Samra, Justin M. Watts, Terrence J. Bradley, Onyee Chan, Mohammad Omar Hussaini, Ling Zhang, Kendra L. Sweet, Andrew T. Kuykendall, Chetasi Talati, Eric Padron, Rami S. Komrokji, Jeffrey E. Lancet, David A. Sallman
Publikováno v:
CancerREFERENCES. 128(21)
Genomic landscape of extramedullary acute myeloid leukemia (EM-AML), including myeloid sarcoma (MS) and leukemia cutis (LC), is not well characterized. The potential utility of next-generation sequencing (NGS) using EM tissue is not established.In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::814d962c9febdfe1f657a28b04050457
https://pubmed.ncbi.nlm.nih.gov/36107670
https://pubmed.ncbi.nlm.nih.gov/36107670
Autor:
Somedeb Ball, Akriti G. Jain, Luis E. Aguirre, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T. Kuykendall, Kendra L. Sweet, Jeffrey E. Lancet, David M. Swoboda, Eric Padron, Rami S. Komrokji, David A. Sallman
Publikováno v:
American Journal of Hematology. 97
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bee6e2d68f3f52fb5a1ea3e9b5c0fd76
https://doi.org/10.1002/ajh.26504
https://doi.org/10.1002/ajh.26504
Autor:
David M. Swoboda, Rashmi Kanagal-Shamanna, Andrew M. Brunner, Thomas Cluzeau, Onyee Chan, Najla Al Ali, Guillermo Montalban-Bravo, Quinto J. Gesiotto, Alexander Gavralidis, Anthony M. Hunter, Jung-Hoon Lee, Andrew T. Kuykendall, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Eric Padron, Mohammad Hussaini, Jinming Song, Guillermo Garcia-Manero, Rami S. Komrokji, David A. Sallman
Publikováno v:
Leukemia. 36(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a303e9fc1b13ae5f54faf774c3c3f1a
https://pubmed.ncbi.nlm.nih.gov/34975158
https://pubmed.ncbi.nlm.nih.gov/34975158
Autor:
David A, Sallman, Amy E, DeZern, Guillermo, Garcia-Manero, David P, Steensma, Gail J, Roboz, Mikkael A, Sekeres, Thomas, Cluzeau, Kendra L, Sweet, Amy, McLemore, Kathy L, McGraw, John, Puskas, Ling, Zhang, Jiqiang, Yao, Qianxing, Mo, Lisa, Nardelli, Najla H, Al Ali, Eric, Padron, Greg, Korbel, Eyal C, Attar, Hagop M, Kantarjian, Jeffrey E, Lancet, Pierre, Fenaux, Alan F, List, Rami S, Komrokji
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(14)
Approximately 20% of patients withThis was a phase Ib/II study to determine the safety, recommended phase II dose, and efficacy of eprenetapopt administered in combination with azacitidine in patients withFifty-five patients (40 MDS, 11 AML, and four
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::691b6c8aac02600499f5a6e3cc2f0335
https://pubmed.ncbi.nlm.nih.gov/33449813
https://pubmed.ncbi.nlm.nih.gov/33449813
Autor:
Quinto J Gesiotto, David M Swoboda, Najla E. Al Ali, Eric Padron, Andrew T. Kuykendall, Jinming Song, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Rami Komrokji, David A. Sallman
Publikováno v:
Blood. 136:4-5
Background: Checkpoint inhibitors, for example anti-PD-1 antibodies (e.g. nivolumab and pembrolizumab) and anti-CTLA-4 antibodies (e.g. ipilimumab), have changed the paradigm of many solid tumors although in myeloid malignancies responses have been l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24a7f661b46d28b3468fb5bad04c415a
https://doi.org/10.1182/blood-2020-140861
https://doi.org/10.1182/blood-2020-140861